PIK3CA and lung adenocarcinoma: In lung adenocarcinoma after erlotinib administration, bypass pathways that activate cell proliferation and invasion, such as the MAPK signaling pathway (tumor stroma) and PI3K-Akt signaling pathway (post-treatment tumor), were activated.